Dr. Trong Tony Trinh, infectious disease specialist at The Polyclinic, is conducting a national research study investigating a new drug for the treatment of recurrent clostridium difficile infection (CDI). CDI is a bacterial infection of the gut (intestines) that causes severe diarrhea, called clostridium difficile-associated diarrhea (CDAD).
CDI has become one of the most common health care associated infections in the U.S., affecting more than 500,000 annually. Approximately 20 to 30 percent of patients with CDI who are treated with commonly used antibiotics experience a recurrence. The risk of recurrence increases with each relapse or reinfection. Currently the only approved treatments available for patients with recurrent disease are more antibiotics or surgery, both of which have limitations.
About the Study Drug
The study drug being investigated by Dr. Trinh is made from fecal matter (stool) collected from a healthy donor, similar to fecal transplant products used in the U.S. today. However, unlike currently available fecal transplant products, the study drug is a preparation containing live, beneficial microorganisms designed to rebuild a healthy balance in the intestines and stop the symptoms of the disease.
Who is Eligible to Participate in the Study?
To be eligible for the study, patients must be 18 years or older and have recurrent CDI that includes at least two episodes of CDI-associated diarrhea, controlled only while taking antibiotics.
Participants will receive the study drug and study-related medical care at no cost. Reimbursement for completed study visits also will be provided.
For additional information about the study, please contact the study coordinator at email@example.com or 206-860-4761.